126 related articles for article (PubMed ID: 26715881)
1. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer.
Lien K; Tam VC; Ko YJ; Mittmann N; Cheung MC; Chan KK
Curr Oncol; 2015 Dec; 22(6):e443-52. PubMed ID: 26715881
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
3. Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients.
Kiadaliri AA; Eliasson B; Gerdtham UG
Health Qual Life Outcomes; 2015 Sep; 13():145. PubMed ID: 26374709
[TBL] [Abstract][Full Text] [Related]
4. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
5. National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
Karlsson JA; Nilsson JÅ; Neovius M; Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2011 Dec; 70(12):2163-6. PubMed ID: 21859684
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of EQ-5D-3L health utility scores using five country-specific tariffs in a rural population aged 45-69 years in Hua county, Henan province, China.
Wang H; Cao C; Guo C; He Y; Li F; Xu R; Liu M; Liu Z; Pan Y; Liu F; Liu Y; Li J; Cai H; He Z; Ke Y
Health Qual Life Outcomes; 2020 Jul; 18(1):228. PubMed ID: 32660494
[TBL] [Abstract][Full Text] [Related]
7. To what extent does the use of crosswalks instead of EQ-5D value sets impact reimbursement decisions?: a simulation study.
Ben ÂJ; van Dongen JM; Finch AP; Alili ME; Bosmans JE
Eur J Health Econ; 2023 Nov; 24(8):1253-1270. PubMed ID: 36371791
[TBL] [Abstract][Full Text] [Related]
8. Assessing the Impact of EQ-5D Country-specific Value Sets on Cost-utility Outcomes.
van Dongen JM; Jornada Ben Â; Finch AP; Rossenaar MMM; Biesheuvel-Leliefeld KEM; Apeldoorn AT; Ostelo RWJG; van Tulder MW; van Marwijk HWJ; Bosmans JE
Med Care; 2021 Jan; 59(1):82-90. PubMed ID: 33201085
[TBL] [Abstract][Full Text] [Related]
9. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
Kim H; Cook G; Goodall S; Liew D
Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
[TBL] [Abstract][Full Text] [Related]
10. EQ-5D Scores for Diabetes-Related Comorbidities.
Sullivan PW; Ghushchyan VH
Value Health; 2016 Dec; 19(8):1002-1008. PubMed ID: 27987626
[TBL] [Abstract][Full Text] [Related]
11. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.
Pilz MJ; Seyringer S; Al-Naesan I; King MT; Bottomley A; Norman R; Schlosser L; Hell T; Gamper EM;
Pharmacoecon Open; 2024 May; ():. PubMed ID: 38696019
[TBL] [Abstract][Full Text] [Related]
12. An International Comparison of EQ-5D-5L and EQ-5D-3L for Use in Cost-Effectiveness Analysis.
Wailoo A; Alava MH; Pudney S; Barton G; O'Dwyer J; Gomes M; Irvine L; Meads D; Sadique Z
Value Health; 2021 Apr; 24(4):568-574. PubMed ID: 33840435
[TBL] [Abstract][Full Text] [Related]
13. Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments.
Yang F; Devlin N; Luo N
Eur J Health Econ; 2019 Feb; 20(1):99-105. PubMed ID: 29948432
[TBL] [Abstract][Full Text] [Related]
14. Comparison of EQ-5D-5L health state utilities using four country-specific tariffs on a breast cancer patient sample in mainland China.
Liu L; Li S; Wang M; Chen G
Patient Prefer Adherence; 2017; 11():1049-1056. PubMed ID: 28706443
[TBL] [Abstract][Full Text] [Related]
15. The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups.
Little MH; Reitmeir P; Peters A; Leidl R
Value Health; 2014 Jun; 17(4):364-71. PubMed ID: 24968996
[TBL] [Abstract][Full Text] [Related]
16. EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom.
Hernandez Alava M; Wailoo A; Grimm S; Pudney S; Gomes M; Sadique Z; Meads D; O'Dwyer J; Barton G; Irvine L
Value Health; 2018 Jan; 21(1):49-56. PubMed ID: 29304940
[TBL] [Abstract][Full Text] [Related]
17. Use of the U.S. and U.K. scoring algorithm for the EuroQol-5D in an economic evaluation of cardiac care.
Shrive FM; Ghali WA; Johnson JA; Donaldson C; Manns BJ
Med Care; 2007 Mar; 45(3):269-73. PubMed ID: 17304086
[TBL] [Abstract][Full Text] [Related]
18. The validity of the EQ-5D-3L items: an investigation with type 2 diabetes patients from six European countries.
Konerding U; Elkhuizen SG; Faubel R; Forte P; Malmström T; Pavi E; Janssen MF
Health Qual Life Outcomes; 2014 Dec; 12():181. PubMed ID: 25479769
[TBL] [Abstract][Full Text] [Related]
19. Adjustment of foreign EQ-5D-3L utilities can increase their transferability.
Oddershede L; Petersen KD
Clinicoecon Outcomes Res; 2015; 7():629-36. PubMed ID: 26719715
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals.
Pennington B; Hernandez-Alava M; Pudney S; Wailoo A
Pharmacoeconomics; 2019 Jan; 37(1):75-84. PubMed ID: 30094806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
